AstraZeneca Pharmaceuticals AB has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
AstraZeneca Pharmaceuticals AB, Sweden, the promoter of AstraZeneca Pharma India, has submitted a declaration to the stock exchanges confirming that it has not created any encumbrance (pledge, lien, or charge) on its shares in the Indian subsidiary during the financial year 1 April 2024 to 31 March 2025. The promoter has further confirmed that all shares held by it in the company are currently free of any encumbrance. The declaration is signed by Lars-Johan Cederbrant, Director and Authorised Signatory, dated 3 April 2025, and is filed in compliance with SEBI's takeover regulations.
This is a routine annual compliance filing and a positive signal for shareholders — it confirms the promoter's stake remains unpledged, reducing concerns about any forced selling risk or margin pressure on the parent holding. No material impact on stock price is expected.